Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
复制标题
液体活检的胶质母细胞瘤效果中的新分子标记。
DOI：
10.3390/ijms21207522
复制
发表时间：
2020-10-12
影响因子：
5.6
通讯作者：
Virga J
中科院分区：
文献类型：
--
作者：
Birkó Z;Nagy B;Klekner Á;Virga J
胶质母细胞瘤是一种原发性中枢神经系统（CNS）恶性肿瘤，生存率低。治疗选择很少，尽管疾病的异质性极大，临床医生缺乏预后和预测标志物来表征不同结果的患者。某些免疫组织化学、FISH或基于pcr的分子标记，包括异柠檬酸脱氢酶1/2 （IDH1/2）突变、表皮生长因子受体变异III （EGFRvIII）突变、血管内皮生长因子过表达（VEGF）过表达或（o6 -甲基鸟嘌呤- dna甲基转移酶启动子）MGMT启动子甲基化状态，都得到了很好的描述；然而，它们的临床实用性和准确性是有限的，并且肿瘤组织样本总是必需的。液体活检在多种类型癌症的诊断和患者随访方面是一个发展中的领域。从不同的体液（包括血清、尿液或脑脊液）中以各种形式收集循环核酸片段，以测量这些标记物的质量和数量。液体活检可以分析多种类型的核酸。循环的无细胞DNA，线粒体DNA，或更稳定的长而小的非编码rna，环状rna，或microrna可以通过新的PCR和下一代基于测序的方法进行鉴定和测量。这些标记可以用微创方法检测先前描述的改变。这些标志物可用于区分预后较差或较好的患者，或识别对治疗无反应的患者。液体活检可用于检测复发性疾病，通常比影像学检查更早。液体活检是一个快速发展的领域，与其他类型的癌症一样，从生物液体样本中测量循环肿瘤来源的核酸可能是胶质母细胞瘤鉴别诊断、患者分层和随访的未来。
Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. Certain immunohistochemistry, FISH, or PCR-based molecular markers, including isocitrate dehydrogenase1/2 (IDH1/2) mutations, epidermal growth factor receptor variant III (EGFRvIII) mutation, vascular endothelial growth factor overexpression (VEGF) overexpression, or (O6-Methylguanine-DNA methyltransferase promoter) MGMT promoter methylation status, are well-described; however, their clinical usefulness and accuracy is limited, and tumor tissue samples are always necessary. Liquid biopsy is a developing field of diagnostics and patient follow up in multiple types of cancer. Fragments of circulating nucleic acids are collected in various forms from different bodily fluids, including serum, urine, or cerebrospinal fluid in order to measure the quality and quantity of these markers. Multiple types of nucleic acids can be analyzed using liquid biopsy. Circulating cell-free DNA, mitochondrial DNA, or the more stable long and small non-coding RNAs, circular RNAs, or microRNAs can be identified and measured by novel PCR and next-generation sequencing-based methods. These markers can be used to detect the previously described alterations in a minimally invasive method. These markers can be used to differentiate patients with poor or better prognosis, or to identify patients who do not respond to therapy. Liquid biopsy can be used to detect recurrent disease, often earlier than using imaging modalities. Liquid biopsy is a rapidly developing field, and similarly to other types of cancer, measuring circulating tumor-derived nucleic acids from biological fluid samples could be the future of differential diagnostics, patient stratification, and follow up in the future in glioblastoma as well.
登录
查看更多内容
DOI：
10.4137/cmo.s7232
发表时间：
2011
期刊：
Clinical Medicine Insights. Oncology
影响因子：
--
作者：
Chamberlain MC
通讯作者：
Chamberlain MC
DOI：
10.1158/1078-0432.ccr-09-3106
发表时间：
2010-04-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Grossman SA;Ye X;Piantadosi S;Desideri S;Nabors LB;Rosenfeld M;Fisher J;NABTT CNS Consortium
通讯作者：
NABTT CNS Consortium
影响因子：
12.7
作者：
Claes A;Idema AJ;Wesseling P
通讯作者：
Wesseling P
影响因子：
1.8
作者：
Cormio A;Guerra F;Cormio G;Pesce V;Fracasso F;Loizzi V;Resta L;Putignano G;Cantatore P;Selvaggi LE;Gadaleta MN
通讯作者：
Gadaleta MN
影响因子：
158.5
作者：
Hegi, ME;Diserens, A;Stupp, R
通讯作者：
Stupp, R